endo-serial-mri-pegvisomant-tumor-size

name	endo-serial-mri-pegvisomant-tumor-size
description	This skill suggests serial MRI imaging to assess tumor size in patients receiving pegvisomant therapy for acromegaly. Use when initiating pegvisomant or during follow‑up to monitor for tumor growth.

Serial MRI to evaluate tumor size during pegvisomant therapy

STEP 1 — Gather Information

Obtain baseline pituitary MRI with pituitary protocol (thin slices, contrast if appropriate) and record current IGF-1 level, symptoms, and date of pegvisomant initiation.

STEP 2 — Rule In / Rule Out

Is the patient currently receiving pegvisomant for acromegaly and without MRI contraindications (e.g., non‑MRI‑compatible device)? If yes, proceed to Step 3; if no, this skill does not apply.

STEP 3 — Classify or Stratify

Determine time since pegvisomant start: <6 months, 6 months, 12 months, or >12 months. Schedule MRI at 6 and 12 months after initiation; if size stable at 1 year, repeat yearly.

STEP 4 — Decide

If MRI shows tumor growth ≥2 mm or new progression, consider discontinuing pegvisomant or adding a somatostatin receptor ligand; if size is stable, continue pegvisomant and repeat imaging per the schedule.

Clinical Guardrails / Mimics / Pitfalls

Do not rely on IGF‑1 alone to assess tumor activity; pegvisomant lowers IGF‑1 without suppressing tumor growth. Avoid MRI intervals shorter than 6 months unless symptomatic change occurs. Ensure MRI includes dynamic pituitary sequences to distinguish true growth from flow‑related artifacts.

Concrete Clinical Example

A 48‑year‑old woman with acromegaly started pegvisomant 15 mg daily. Baseline MRI showed a 12 mm macroadenoma abutting the cavernous sinus. At 6‑month MRI size unchanged; at 12‑month MRI unchanged. She continues pegvisomant with yearly MRI surveillance.

Source: Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2700